| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Research Abstract |
Erom established monoclonal antibodies for lung cancder, I selected useful early sero-diagnostic markers. As a results, anti-CAXII antibody was reported as asero-diagnostic marker (PLOS ONE 7(3): e33952, 2012). In addition, I submitted that antiBSG and MHY9 antibodies were useful markeres for pathological diagnosis of lung cancer. Ant-IMMT antibody was established as a sensitivity prediction marker of the platinum.
By the analysis of tumor-associated autoantibodies, I reported antiHu-C, Hu-D autoantibodies were novel differential sero-diagnostic markers for small cell lung carcinoma from large cell neuroendocrine carcinoma (Int J Oncol 40: 1957-1962, 2012).Ant-Galectin-3 autoantibody was found as an anticancer drug sensitivity prediction marker. And, I reported methodology that aquisition of useful sero-diagnostic autoantibodies using the same patients' sera and tumor tissues (Biomed Res 35(2): 133-143, 2014.
|
